Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02223819 |
| Title | Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Memorial Sloan Kettering Cancer Center, Pfizer |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | United States | Details | |
| Columbia Univeristy Medical Center | New York | New York | 10032 | United States | Details | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| The Ohio State University | Columbus | Ohio | 43210 | United States | Details |